The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging ...

A panelist discusses how patient-reported outcomes and real-world evidence contribute valuable insights into the practical impact of these treatments, complementing traditional efficacy measures and ...

The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed ...

An expert discusses the patient case of a 65-year-old woman who has presented to the emergency department with abdominal pain. The patient’s previous medical issues include a duodenal ulcer that she ...

An expert discusses how, in third line (3L) therapy, goals shift from optimal disease control to managing treatment-resistant disease while preserving quality of life. Unlike 2L therapy where ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients ...

According to Auletta, addressing these disparities requires a collective, ecosystem-wide effort in order to ensure better representation and access for vulnerable patients in stem cell transplants and ...

Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...